Samsung Biologics Co Ltd (207940) — Long-term Investment Intensity

Latest as of December 2018: 43.2%

Samsung Biologics Co Ltd (207940) has a Long-term Investment Intensity of 43.2% as of December 2018. Long-term investments of ₩2.59 Trillion represent 43.2% of total assets of ₩5.98 Trillion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Samsung Biologics Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

LT Investment Intensity

43.2%
LT Investments / Total Assets

Long-term Investments

₩2.59 Trillion
KRW

Total Assets

₩5.98 Trillion
KRW

Country

Korea
KO

Samsung Biologics Co Ltd Long-term Investment Intensity (2014–2018)

This chart shows how Samsung Biologics Co Ltd's Long-term Investment Intensity has evolved across 5 annual periods from 2014 to 2018. As of December 2018, the intensity stands at 43.2%, reflecting long-term investments of ₩2.59 Trillion against total assets of ₩5.98 Trillion KRW. For the complete balance sheet picture, see Samsung Biologics Co Ltd assets under control.

Annual Long-term Investment Intensity for Samsung Biologics Co Ltd (2014–2018)

The table below presents the year-by-year Long-term Investment Intensity for Samsung Biologics Co Ltd from 2014 to 2018, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read 207940 current and long-term liabilities for a breakdown of total debt and financial obligations.

Year LT Investment Intensity LT Investments (KRW) Total Assets Change (pp)
2018 43.2% ₩2.59 Trillion ₩5.98 Trillion ▼ -26.5 pp
2017 69.7% ₩5.01 Trillion ₩7.18 Trillion ▲ +4.1 pp
2016 65.6% ₩4.94 Trillion ₩7.53 Trillion ▼ -15.5 pp
2015 81.2% ₩4.84 Trillion ₩5.96 Trillion ▲ +77.2 pp
2014 4.0% ₩53.92 Billion ₩1.36 Trillion
pp = percentage points